Physician profile
Michael K Johnson
NPI 1174574172
$12,839.29
in general payments reported to CMS, 2019-2025
40 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,208 · 2020: $2,072 · 2021: $2,459 · 2022: $1,554 · 2023: $1,746 · 2024: $1,453 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,476 · Education: $70.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,476.13 |
| Education | $70.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,134.49 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,292.61 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $1,264.17 | 2019-2022 | |
| Lilly USA, LLC | $912.21 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $889.18 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $673.65 | 2019-2021 | |
| Astellas Pharma US INC | $626.33 | 2019-2024 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $489.01 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.81 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $313.27 | 2019-2025 | Repatha, Otezla, Repatha |
| Lundbeck LLC | $244.65 | 2023-2025 | Rexulti |
| Sk Life Science, INC. | $233.39 | 2023-2024 | Xcopri |
| Pfizer INC. | $199.43 | 2019-2025 | |
| Abbott Laboratories | $194.70 | 2020-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $187.56 | 2024-2025 | Rexulti |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.